Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Johnson & Johnson (JNJ) vs Uranium Energy Corp (UEC) Price & Performance

Johnson & JohnsonTrade
Uranium Energy CorpTrade

Price performance (Past 24H)

Key statistics

Johnson & Johnson vs Uranium Energy Corp — how do they compare? Johnson & Johnson trades at $260.7 (market cap $626.09B), while Uranium Energy Corp trades at $11.39 (market cap $5.67B). The key difference: Johnson & Johnson is far larger — about 110.4× Uranium Energy Corp's market cap, and Johnson & Johnson pays a 2.06% dividend while Uranium Energy Corp pays none. Which is the better fit depends on your goals.

JNJUEC
Market Cap
$626.09B$5.67B
Volume
6,156,228
Sector
HealthEnergy
52-Week High
$267.24$20.14
52-Week Low
$172.78$9.04
Enterprise Value
$654.37B$5.18B
Dividend Yield
2.06%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Johnson & Johnson

Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.

Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.

Uranium Energy Corp

UEC trades at $11.36, down 0.18% on the day, with a bullish technical signal driven by moving averages despite a neutral oscillator reading. The company reported a net loss of $87.66 million in 2025, with revenue of $66.84 million, and faces significant profitability challenges with a negative net income margin of -513.24%. Recent news highlights insider selling and optimistic long-term uranium market forecasts.

Outlook hinges on uranium price recovery and production ramp-up, but risks include persistent losses, high valuation multiples, and execution delays. Analyst consensus is strongly bullish with 87.5% buy ratings, though fundamentals warrant caution due to cash burn and competitive pressures.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Johnson & Johnson

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.

Read more on JNJ

About Uranium Energy Corp

Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.

Read more on UEC